Effects of zidovudine, stavudine and β-aminoisobutyric acid on lipid homeostasis in mice: Possible role in human fat wasting

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 801-810

  Maisonneuve, Caroline ^a   Igoudjil, Anissa ^a   Begriche, Karima ^a   Lettéron, Philippe ^a   Guimont, Marie Christine ^b   Bastin, Jean ^c   Laigneau, Jean Pierre ^a   Pessayre, Dominique ^a   Fromenty, Bernard ^a  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 METHYLPROPIONIC ACID; ADIPONECTIN; CHOLESTEROL; DIDANOSINE; GLUCOSE; INSULIN; LEPTIN; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BODY FAT; CONTROLLED STUDY; DNA DETERMINATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIDIDYMIS FAT; FATTY ACID OXIDATION; FATTY LIVER; FOOD INTAKE; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER METABOLISM; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REPRODUCIBILITY; SLOT BLOT HYBRIDIZATION; WASTING SYNDROME;

AMINOISOBUTYRIC ACIDS; ANIMALS; ANTI-HIV AGENTS; BODY WEIGHT; HOMEOSTASIS; LIPID METABOLISM; LIPODYSTROPHY; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THINNESS; ZIDOVUDINE;

EID: 7244221843     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner TS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283:381-390.
2. Brinkman, K, Smeitink JA, Romijn JA & Reiss P. Hypothesis: mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
3. Carr A & Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
4. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G, Flepp M & Telenti A. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet 2001; 358:1322-1327.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
6. Powderly WG. Long-term exposure to lifelong therapies. Journal of Acquired Immune Deficiency Syndromes 2002; 29:S28-S40.
7. Panther LA. How HIV infection and its treatment affects the cardiovascular system: what is known, what is needed. American Journal of Physiology. Heart Circulatory Physiology 2002; 283:H1-H4.
8. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouvière O, Lang JM, Gastaut JA & Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.
9. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP & Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.
10. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P & Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
11. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP & Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antiviral Therapy 2004; 9:161-177.
12. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF & Wesselingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. Journal of Acquired Immune Deficiency Syndromes 2002; 30:271-277.
13. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B & Mallal S. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
14. Note R, Maisonneuve C, Letteron P, Peytavin G, Djouadi F, Igoudjil A, Guimont MC, Biour M, Pessayre D & Fromenty B. Mitochondrial and metabolic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments. Antimicrobial Agents & Chemotherapy 2003; 47:3384-3392.
15. Gaou I, Malliti M, Guimont MC, Lettéron P, Demeilliers C, Peytavin G, Degott C, Pessayre D & Fromenty B. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. Journal of Pharmacology & Experimental Therapeutics 2001; 297:516-523.
16. Li B, Nolte LA, Ju JS, Han DH, Coleman T, Holloszy JO & Semenkovich CF. Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nature Medicine 2000; 6:1115-1120.
17. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V & Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Letters 2001; 491:154-158.
18. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ & Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochemical & Biophysical Research Communications 2002; 296:293-299.
19. Changani KK, Nicholson A, White A, Latcham JK, Reid DG & Clapham JC. A longitudinal magnetic resonance imaging (MRI) study of differences in abdominal fat distribution between normal mice and lean overexpressors of mitochondrial uncoupling protein-3 (UCP-3). Diabetes, Obesity & Metabolism 2003; 5:99-105.
20. Friedman JM & Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395:763-770.
21. Koteish A & Diehl AM. Animal models of steatosis. Seminars in Liver Disease 2001; 21:89-104.
22. Lettéron P, Fromenty B, Terris B, Degott C & Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. Journal of Hepatology 1996; 24:200-208.
23. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, Lettéron P & Pessayre D. Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. Journal of Pharmacology & Experimental Therapeutics 1990; 255:1371-1376.
24. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, Lettéron P, Degott C, Feldmann G, Pessayre D & Fromenty B. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002; 123:1278-1290.
25. Hassett RP & Crockett EL. Endpoint fluorometric assays for determining activities of carnitine palmitoyltransferase and citrate synthase. Analytical Biochemistry 2000; 287:176-179.
26. McGarry JD & Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annual Review of Biochemistry 1980; 49:395-420.
27. Fromenty B & Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacology & Therapeutics 1995; 67:101-154.
28. Walker UA, Bickel M, Lütke Volksbeck SI, Ketelsen UP, Schöfer H, Setzer B, Venhoff N, Rickerts V & Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 29:117-121.
29. Lombardo YB, Hron WT, Sobocinski KA & Menahan LA. A metabolic profile of fed and fasting genetically obese mice at 4-5 months of age. Hormone & Metabolic Research 1983; 16(Suppl):37-42.
30. Camus MC, Aubert R, Bourgeois F, Herzog J, Alexiu A & Lemonnier D. Serum lipoprotein and apolipoprotein profiles of the genetically obese ob/ob mouse. Biochimica et Biophysica Acta 1988; 961:53-64.
31. Drynan L, Quant PA & Zammit VA. The role of changes in the sensitivity of hepatic mitochondrial overt carnitine palmitoyltransferase in determining the onset of the ketosis of starvation in the rat. Biochemical Journal 1996; 318:767-770.
32. Cook GA & Gamble MS. Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. Journal of Biological Chemistry 1987; 262:2050-2055.
33. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E & Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-2093.
34. Himms-Hagen J & Harper ME. Physiological role of UCP-3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Experimental Biology & Medicine 2001; 226:78-84.
35. Cretton EM, Zhou Z, Kidd LB, McClure HM, Kaul S, Hitchcock MJM & Sommadossi JP. In vitro and in vivo disposition and metabolism of 3′-deoxy-2′,3′-didehydrothymidine. Antimicrobial Agents & Chemotherapy 1993; 37:1816-1825.
36. Patterson TA, Binienda ZK, Newport GD, Lipe GW, Gillam MP, Slikker W & Sandberg JA. Transplacental pharmacokinetics and fetal distribution of 2′,3′-didehydro-3′-deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. Teratology 2000; 62:93-99.
37. 14C]thymidine in mice. Journal of Pharmacology & Experimental Therapeutics 1991; 257:479-486.
38. Nicolas F, De Sousa G, Thomas P, Placidi M, Lorenzon G & Rahmani R. Comparative metabolism of 3′-azido-3′-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans. Drug Metabolism & Disposition 1995; 23:308-313.
39. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ & Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. Journal of Biological Chemistry 2001; 276:37514-37519.
40. Estrada V, Serrano-Rios M, Martinez Larrad MT, Villar NG, Gonzalez Lopez A, Téllez MJ & Fernandez C. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2002; 29:32-40.
41. Nagy GS, Tsiodras S, Martin LD, Avihingsanon A, Gavrila A, Hsu WC, Karchmer AW & Mantzoros CS. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clinical Infectious Diseases 2003; 36:795-802.
42. Berg AH, Combs TP & Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinology & Metabolism 2002; 13:84-89.
43. Tone Q, Sankalé JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK & Hotamisligil GS. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. Journal of Clinical Endocrinology & Metabolism 2003; 88:1559-1564.
44. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW & Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. Journal of Clinical Endocrinology & Metabolism 2003; 88:627-636.